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ABSTRACT
The joint distributions of the six genes bca, bac,  ⁄ alp1, alp2, alp3 and rib (encoding a-C-protein,
b-C-protein,  ⁄Alp1, Alp2, Alp3, and Rib, respectively) and the proteins a-C-protein, b-C-protein and
Rib were investigated in invasive isolates of group B streptococcus (GBS). In total, 297 invasive isolates
(123 from neonates, 174 from adults) from south-west Sweden were collected during a 13-year period.
Genes were detected using multiplex and specific PCRs, and expression of the surface proteins was
demonstrated using monoclonal antibodies. The genes studied were found alone or in combinations in
294 (99%) of the invasive isolates. The most common genes were rib (n = 127 isolates, 43%), alp3 (n = 78,
26%) and  ⁄ alp1 (n = 42, 14%). The bac gene was never found alone, but was found in combination with
one other gene in 36 isolates. The surface proteins studied were detected alone or in combinations in 152
(51%) isolates, with the most common being Rib (n = 80, 27%), a-C-protein (n = 68, 23%) and b-C-
protein (n = 24, 8%). Several genes were associated significantly with particular serotypes (e.g.,  ⁄ alp1
with serotype Ia; bca and bac with serotypes Ib and II; rib with serotype III; alp3 with serotype V).
Overall, it was concluded that demonstration of different genes and surface proteins of GBS strains can
be useful in epidemiological studies and in formulation of vaccines, but disappointingly, no single gene
or surface protein included in the study was sufficiently common for it to be considered as the basis for a
successful GBS vaccine.
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INTRODUCTION
The importance of Streptococcus agalactiae
(group B streptococcus; GBS) as a major pathogen
in invasive neonatal infections and infections in
pregnant women is well-documented [1–7]. GBS
is also increasingly common as a pathogen caus-
ing severe infections in adults with underlying
medical conditions [8,9]. Since recommendations
for intra-partum antibiotics for mothers in labour
at risk of GBS infection have been widely
implemented, the incidence of early-onset GBS
infection has declined to <1 ⁄ 1000 live births [1–7].
However, the incidence of late-onset disease has
not declined. An attractive alternative to intra-
partum antibiotics would be vaccination of young
women to protect their neonates against GBS
infection. An effective vaccine might protect a
large proportion of neonates against early- and
late-onset GBS sepsis, and might also prevent
GBS-related still-births and premature births.
Based on the capsular polysaccharide (CPS)
antigens, nine GBS serotypes (Ia, Ib, II–VIII) have
been recognised to date. The major serotypes
that cause invasive infections in both neonates
and adults are serotypes III, V and Ia [2–6,8,9].
Antibodies against CPS provide type-specific
protection [10], and a multivalent conjugate
vaccine, containing serotypes Ia, Ib, II, III and V
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conjugated with a protein, has been a major focus
of interest. Conjugate vaccines composed of CPS
and tetanus toxoid have been evaluated in
healthy adults [11,12], and a type III CPS–tetanus
toxoid conjugate vaccine has been tested in
women at 31–32 weeks of gestation [13].
GBS can also be classified on the basis of
surface protein antigens. The first surface protein
identified in GBS was the C antigen [14]. The C
antigen is composed of the a and b proteins
[15]. A GBS strain can express a-C-protein or b-C-
protein, or both. The major surface-localised
proteins include a-C-protein and b-C-protein,
the R-proteins R1, R3 and R4 (the last of these
has been shown to be identical to Rib [16,17]), and
the a-like proteins Alp2 and Alp3 [18,19], which
may be variants of R1 protein [20]. The  protein
has also been called a-like protein Alp1. Several of
the surface protein antigens induce protective
immunity in animal models [15,21,22], and sur-
face proteins common for many strains would
have a potential role in vaccine development.
The bca,  ⁄ alp1, bac, rib, alp2 and alp3 genes
encode a-C-protein,  ⁄Alp1, b-C-protein, Rib,
Alp2 and Alp3, respectively. Studies of surface
proteins, and of the genes encoding these pro-
teins, are important for epidemiological analysis
of GBS infections, and may also be of use in the
development of a GBS vaccine that is suitable for
use in widespread geographical areas. Accord-
ingly, the aims of the present study were to
analyse the gene content and surface protein
distributions among invasive GBS isolates from a
defined geographical area, to monitor the popu-
lation dynamics over a 13-year period, and to
compare the distribution of the different genes
and proteins among age groups and capsular
serotypes. An additional aim was to identify
surface protein antigens that might be of use in
the development of GBS vaccines.
MATERIALS AND METHODS
Invasive GBS isolates were collected as part of two previous
studies conducted in south-west Sweden. In total, 136 invasive
GBS isolates from the first study, collected between 1988 and
1997 at the Department of Clinical Bacteriology, Sahlgrenska
Hospital, Go¨teborg, or between 1995 and 1997 from four other
bacteriological laboratories in south-west Sweden [23], were
available for the present investigation. In the second study, 161
invasive GBS isolates were collected prospectively between
1998 and 2001 from the six bacteriological laboratories in the
counties of Va¨stra Go¨taland and Halland in south-west
Sweden [5]. These laboratories serve all 13 hospitals in the
two counties. The mean population of the surveillance area
was 1 767 215, and the total number of live births during the
entire study period was 298 639 (http://www.scb.se). Of the
297 isolates, 143 were from female and 154 were from male
patients, with 123 isolates from neonates and infants aged
0–180 days, and 174 from adults aged 19–96 years.
GBS isolates were collected from normally sterile samples
(blood, cerebrospinal fluid and synovial fluid). Isolates were
identified as GBS according to colony morphology, microscopy
following Gram’s stain of smears, and coagglutination with
group-specific reagents (Streptest; Murex Biotec, Dartford,
UK). The isolates were initially stored in broth at )70C, and
then freeze-dried and transported to St Olav’s University
Hospital, Trondheim, where surface protein typing and geno-
typing were performed. Only one isolate from each infectious
episode was included in the study. Clinical data (age, gender,
gestational age, underlying medical conditions, clinical mani-
festations and outcome) were obtained from the individual
hospital notes of the patients. All hospital notes and relevant
data were available for all patients. At the time of the second
study (1998–2001), the policy at most of the hospitals for intra-
partum antimicrobial prophylaxis was that recommended by
the American College of Obstetricians and Gynecologists [24].
Antibody-based surface protein typing was performed
using murine monoclonal antibodies against GBS a-C-protein,
b-C-protein and Rib in an indirect whole-cell-based fluorescent
antibody test, using reagents and methods described previ-
ously [25]. The resulting fluorescence, detected using a Nikon
epifluorescence microscope, was graded from 0 to 3+, with
scores of 2+ and 3+ being indicative of a positive test.
A multiplex PCR [26] was used to detect bca,  ⁄ alp1, rib and
alp2 ⁄ alp3, encoding a-C-protein,  ⁄Alp1, Rib and Alp2 ⁄Alp3,
respectively. Primers were synthesised by Eurogentech SA
(Liege, Belgium). All isolates positive by PCR for alp2 ⁄ alp3 were
further tested by alp2- and alp3-specific PCRs. All isolates were
examined for bac, encoding b-C-protein, using primer pairs as
specified previously [27]. Bacterial lysates were prepared as
described previously [28]. PCR products were detected using
an Agilent 2100 Bioanalyzer (Agilent Technologies, St Clara,
CA, USA) as recommended by the manufacturer.
The capsular serotypes of the isolates included in this study
have been described previously [5,23].
Statistical analysis
Proportions were compared using two-tailed Fisher’s exact
tests with the Bonferroni correction for multiple comparisons.
Ethical approval
The Central Ethics Review Board of Go¨teborg University and
Lund University approved the two studies.
RESULTS
Surface proteins
The surface a-C-protein, b-C-protein and Rib
were detected alone or in combinations in 152
(51%) of the 297 isolates. The most commonly
Persson et al. Characterisation of invasive group B streptococci 67
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 66–73
detected protein was Rib (n = 80, 27%), followed
by a-C-protein (n = 68, 23%). The most common
combination was a- and b-C-protein (n = 21, 7%)
(Table 1).
Gene content
The six genes investigated (bca, bac, rib,  ⁄ alp1,
alp2 and alp3) were identified alone or in combi-
nations in 294 (99%) of the 297 GBS isolates. The
most common gene identified alone was rib
(n = 126, 42%), followed by alp3 (n = 77, 26%)
and  ⁄ alp1 (n = 42, 14%). The most common
combination was bca and bac (n = 33, 11%)
(Table 2). The alp2 gene was only detected in four
isolates. All combinations of genes included bac;
indeed, bac was never found alone, but only in
combination with other genes.
Correlation between gene content and surface
proteins
The correlation between genes and surface pro-
teins is summarised in Table 3. The  ⁄ alp1 and bca
genes were more common in isolates in which a-
C-protein was detected than in the sum of all
other isolates (for  ⁄ alp1, 31 ⁄ 68 vs. 11 ⁄ 229,
p <0.0001; for bca, 36 ⁄ 68 vs. 7 ⁄ 229, p <0.0001).
The  ⁄ alp1 or bca genes were found in 67 ⁄ 68
(98.5%) of isolates positive for a-C-protein. Sur-
prisingly, bca was also more common in isolates in
which b-C-protein was detected (24 ⁄ 25 vs. 19 ⁄ 272,
p <0.0001), even though this gene does not
encode b-C-protein. The bac gene was more
common in isolates in which b-C-protein was
detected (21 ⁄ 25 vs. 15 ⁄ 272, p <0.0001), and rib
was more common in isolates in which Rib was
detected (72 ⁄ 80 vs. 55 ⁄ 217, p <0.0001). All of the
eight Rib-positive, rib-negative isolates contained
alp3.
The a-C-protein was detected in 31 (74%) of 42
 ⁄ alp1-positive isolates, and also in 36 (84%) of 43
bca-positive isolates. b-C-protein was detected
in 21 (58%) of 36 bac-positive isolates. Rib
surface protein was detected in 72 (57%) of 127
rib-positive isolates, and also in eight of 78
alp3-positive isolates.
Correlation among serotype, gene content and
surface proteins
The distributions of genes and surface proteins
among the different capsular serotypes are shown
in Tables 4 and 5, respectively. Most genes and
surface proteins were detected in isolates of all
capsular serotypes. However, certain types were
associated significantly with specific serotypes
Table 1. Surface proteins detected using fluorescent anti-
body tests in invasive group B streptococci isolated from
neonates and adults
Surface protein
No. of isolates (%)
Neonates Adults Total
Rib 43 (35) 37 (21) 80 (27)
a-C-protein 22 (18) 25 (14) 47 (16)
b-C-protein 1 (1) 3 (2) 4 (1)
a-C-protein and b-C-protein 2 (2) 19 (11) 21 (7)
None detected 55 (45) 90 (52) 145 (49)
Total 123 174 297
Table 2. Genes encoding surface proteins found among
invasive group B streptococci isolated from neonates and
adults
Gene
No. of isolates (%)
Neonates Adults Total
rib 74 (60) 52 (30) 126 (42)
alp3 19 (15) 58 (33) 77 (26)
 ⁄ alp1 22 (18) 20 (11) 42 (14)
bca and bac 6 (5) 27 (16) 33 (11)
bca 10 (6) 10 (3)
alp2 1 (1) 2 (1) 3 (1)
alp2 and bac 1 (1) 1 (0.3)
alp3 and bac 1 (1) 1 (0.3)
Rib and bac 1 (1) 1 (0.3)
None detected 1 (1) 2 (1) 3 (1)
Total 123 174 297
Table 3. Correlation between gene content and surface proteins
Surface proteins
Genes
rib alp3  ⁄ alp1 bca and bac bca alp2 alp2 and bac alp3 and bac rib and bac None detected Total
Rib 71 8 1 80
a-C-protein 31 12 4 1 48
b-C-protein 3 1 4
a- and b-C-proteins 17 3 20
None detected 55 69 11 1 3 3 1 2 145
Total 126 77 42 33 10 3 1 1 1 3 297
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(e.g.,  ⁄ alp1 with serotype Ia; bca and bac with
serotypes Ib and II; rib with serotype III; and alp3
with serotype V) (Table 6). a-C-protein was asso-
ciated significantly with serotypes Ia, Ib and II,
b-C-protein was associated with serotypes Ib and
II, and Rib protein was associated with sero-
type III (Table 6).
Differences between neonates and adults
The differences in the distributions of surface
proteins and their corresponding genes according
to serotype among neonates and adults are
summarised in Table 7. The rib gene was more
common among neonates than among adults
(74 ⁄ 123 vs. 53 ⁄ 174, p <0.0001). The alp3 gene
was more common among adults than among
neonates (59 ⁄ 174 vs. 19 ⁄ 123, p <0.0005). There
were no differences in protein expression
between the age groups. The differences found
could be explained by differences in serotypes
between the two age groups; serotype III dom-
inated among neonates (p <0.0001), while sero-
type V dominated among adults (p 0.0002).
There were no significant changes in gene
content or surface proteins during the 13-year
period in which the study isolates were
collected (results not shown).
DISCUSSION
To date, epidemiological studies of GBS infec-
tions have used a classification according to CPS
and surface proteins, and several methods have
been devised for serotyping [29–31]. Variations
in serotype ⁄ surface proteins have provided an
important tool for following GBS infections in a
population [1–6]. However, a weakness of anti-
body-based surface protein typing is that several
strains can react with two or more antisera,
indicating a high degree of cross-reactivity [32].
GBS strains show considerable variations at the
genetic level, and genes under strong environ-
mental selection may undergo mutations that are
not detected by PCR. Genotyping methods,
including pulsed-field gel electrophoresis, mul-
tilocus enzyme electrophoresis and multilocus
sequence typing, have been used to characterise
and distinguish specific clones among GBS iso-
lates [33–36]. Molecular serotyping methods for
CPS have also been established [37,38]. In the
present study, fluorescent antibody tests and
PCRs were used to characterise invasive GBS
Table 4. Correlation between cap-
sular serotype and gene content in
















Ia 2 2 22 2 2 1 1 32
Ib 3 1 17 5 1 27
II 1 8 10 1 1 1 22
III 116 3 1 1 122
IV 4 2 5 1 12
V 67 3 1 1 1 2 77
Not typeable 1 2 1 5
Total 126 77 42 33 10 3 1 1 1 3 297
Table 5. Correlation between capsular serotype and sur-









Ia 19 2 11 32
Ib 2 11 1 8 5 27
II 1 8 2 7 4 22
III 65 2 54 121
IV 4 4 1 5 14
V 7 2 1 66 76
Not typeable 1 2 1 4
Total 80 48 4 20 145 297
Table 6. Significant associations between gene content
and serotype, and between surface protein and serotype
Gene ⁄ specific serotype Gene ⁄ other serotypes p
 ⁄ alp1 in Ia 22 ⁄ 32 (69%) 20 ⁄ 265 (8%) <0.0001
bac in Ib 18 ⁄ 27 (67%) 18 ⁄ 270 (7%) <0.0001
bca in Ib 22 ⁄ 27 (81%) 21 ⁄ 270 (8%) <0.0001
bac in II 11 ⁄ 22 (50%) 25 ⁄ 275 (9%) 0.0001
bca in II 11 ⁄ 22 (50%) 32 ⁄ 275 (12%) 0.0008
rib in III 116 ⁄ 122 (95%) 11 ⁄ 175 (6%) <0.0001
alp3 in V 67 ⁄ 77 (87%) 10 ⁄ 220 (5%) <0.0001
rib in V 1 ⁄ 77 (1%) 126 ⁄ 220 (57%) <0.0001
Protein ⁄ serotype Protein ⁄ other serotypes
a-C-protein in Ia 21 ⁄ 32 (66%) 47 ⁄ 265 (18%) <0.0001
Rib in III 65 ⁄ 122 (53%) 15 ⁄ 176 (8%) <0.0001
a-C-protein in Ib 19 ⁄ 27 (70%) 49 ⁄ 270 (18%) <0.0001
a-C-protein in II 15 ⁄ 22 (68%) 53 ⁄ 275 (19%) <0.0001
b-C-protein in Ib 9 ⁄ 27 (33%) 15 ⁄ 270 (6%) 0.0004
b-C-protein in II 9 ⁄ 22 (41%) 15 ⁄ 275 (5%) 0.0001
Persson et al. Characterisation of invasive group B streptococci 69
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 66–73
isolates on the basis of surface proteins and their
corresponding genes.
The genes encoding surface proteins were
found to constitute a heterogeneous group, with
no particular gene dominating, either alone or in
combination with others. The genes studied were
found in 99% of the invasive isolates, either alone
or in nine different combinations. The overall
distribution of these genes was similar to that
reported previously [18,27,37]. The three proteins
studied were found at high frequencies (57–84%)
in isolates harbouring the corresponding genes,
and vice versa (84–98.5%), but the correlations
were not complete.
The surface proteins of GBS are likely to play an
important role during different stages of GBS
infection. They confer immunity in animal models
[15,21,22] and are therefore considered to be of
potential importance in vaccine development.
a-C-protein and  ⁄Alp1, Rib, Alp2 and Alp3 all
belong to the group of ladder-forming proteins.
Individual proteins exhibit extended regions
composed of long identical repetitions [39].
Sections of the ladder-forming proteins show
sequence homology. The proteins are highly
complex immunologically, and have both pro-
tein-specific sites and sites that are similar [18].
The surface proteins included in the present
study, i.e., a-C-protein, b-C-protein and Rib, were
detected in only 51% of the invasive GBS isolates
studied (neonates 55%, adults 48%), which is in
contrast with results from other studies in Europe
and the USA, in which the detection rates were
higher (70–90%) [4,40]. In the present study, there
was a higher proportion of serotype V strains
[4,40,41]. Serotype V often carries alp3, against
which no antiserum exists. This might have
contributed to the lower expression rate of surface
proteins found in the present study. Alternatively,
the proteins might have been expressed in insuf-
ficient quantities to be detected by the antibody-
based test used. Furthermore, it is not known
whether the expression rate under in-vitro growth
conditions is the same as that in vivo.
Rib was found less commonly than in a study
from the USA [40]. This difference could be
caused by geographical variation, a lower expres-
sion rate, or the use of a Rib monoclonal antibody
in the present study. In contrast, rib was found at
a higher frequency (43%) in the present study
than in another study from the USA (28%) [41].
This second US study found bca in 29% of
isolates, compared with only 14% of isolates in
the present study. The difference in the propor-
tion of bac was less pronounced (12% in the
present study vs. 20% in the US study).
It has been shown previously that Alp3 pos-
sesses an antigenic determinant that is also
present in Rib. This region is called the Rib ⁄Alp3
common site, and explains the cross-reactivity
between these proteins [20, 42]. In serotype V, the
dominant surface protein gene is alp3 (p <0.0001)
encoding Alp3 [19]. In the present study, eight of
78 isolates with alp3 also expressed Rib, and all 80
Table 7. Correlation of capsular serotypes of group B streptococci with surface proteins and gene content, stratified





Ca Ca, Cb Cb Rib
Total bca, bac bca n bca, bac bca bca, bac bac, alp2 bac rib alp3 rib, bac rib  bca bca, bac alp2 alp3 alp3, bac n
Neonate Ia 12 1 1 2 1 1 18
Ib 2 2 4
II 3 1 1 5
III 1 42 30 1 74
IV 2 1 3
V 1 16 1 18
NT 1 1
Total 19 3 2 1 42 1 32 3 1 18 1 123
Adult Ia 5 1 1 1 1 3 1 1 14
Ib 1 6 2 6 1 1 1 1 2 1 2 24
II 3 2 6 1 1 1 1 1 1 17
III 1 23 22 1 47
IV 1 1 1 4 2 2 11
V 1 1 1 6 2 1 45 1 58
NT 1 1 1 3
Total 12 9 4 1 15 3 2 1 29 7 1 23 8 3 1 2 51 1 1 174
Ca, a-C-protein; Cb, b-C-protein; R4, Rib protein; ,  ⁄ alp1 gene; n, not found.
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Rib-positive isolates harboured either rib or alp3.
This could be a result of the Rib ⁄Alp3 common site.
Antibodies targeting the Rib ⁄Alp3 common deter-
minant could hamper the reliability of Rib detec-
tion by antibody-based methods. Alp3 possesses
several sites for antibody binding, but only con-
tains antigenic determinants that are shared with
other streptococcal proteins. It may therefore be
difficult to produce Alp3-specific antibodies [42].
GBS can traverse placental membranes and
weaken their tensile strength, gain access to the
foetus within the amniotic cavity, induce placen-
tal membrane rupture and ⁄ or trigger premature
delivery. The lung of the neonate is the initial
focus for GBS infection, leading to free access to
the bloodstream. Invasive strains enter epithelial
cells more efficiently than strains from the vaginal
mucosa of asymptomatic women [43]. The surface
proteins play an important role in the pathogen-
esis of GBS infection. It has been shown that
strains passing from mother to neonate may
undergo mutations in bca, encoding a-C-protein,
and that these mutations coincide with a loss of
susceptibility to antibody-mediated killing by
polymorphonuclear leukocytes [44,45].
The CPS antibodies confer protective immunity
[10], and the capsule protects the bacteria from
phagocytosis. The capsular serotype distribution
varies over time, among different countries and
among populations. The most important serotypes
among invasive GBS strains infecting neonates are
currently serotypes III, V and Ia. Serotype III is the
serotype found most frequently among neonates
in both Europe and North America [1–7]. The
present study confirmed relationships reported
previously among serotypes and genes encoding
surface proteins [27,29,32,33]. Significant associa-
tions between serotype Ia and  ⁄ alp1, between
serotype III and rib, between serotype V and alp3,
and between serotypes Ia, Ib and II and bca and
bac, were found, but the associations were not
absolute, and many different combinations of
genes were seen in most serotypes.
Vaccine development for GBS has focused on
CPS antigens, with studies showing that conju-
gated polysaccharide vaccines are well-tolerated
[11–14]. Unconjugated polysaccharides are poorly
immunogenic, but a covalent coupling with
proteins stimulates a T-cell-dependent antigenic
recognition that profoundly enhances immuno-
genicity. There are several immunogenic GBS
surface proteins that could be carriers for the CPS
antigens, and ⁄ or act as protective antigens them-
selves. In a vaccine study in mice [46], a-C-protein
was covalently coupled with serotype III CPS and
was shown to be an effective carrier. Rib also
protected mice, without coupling to polysaccha-
rides [47]. Several studies have attempted to
identify a single protective protein that would
be present in all strains. Sip, present in all strains,
generates an immune response and protection
against invasive GBS infection in animal models
[48], and has shown promise as a vaccine candi-
date, but further studies have shown that the
surface accessibility of Sip depend on the pres-
ence of the CPS [49].
Protein antigens resulting in protection have
been shown to be effective only against those
strains in which the antigens are sufficiently
exposed on the bacterial surface, even though
the strain carries the corresponding encoding
genes [49]. A CPS conjugate vaccine for this
population would need a combination of several
CPSs and ⁄ or protein antigens. The variability in
surface antigen expression makes it very impor-
tant to select strains with high expression and
accessibility of the antigen when developing a
vaccine formula. Development of effective vac-
cines and implementation of vaccine strategies
will be one of the key future challenges for
prevention of neonatal GBS infections.
The isolates in the present study were obtained
from both children and adults. Elderly individu-
als and patients with underlying disease have an
increased risk of invasive GBS infection. In this
group of patients, almost nothing is known
concerning potentially protective CPS or protein
antibodies. The alp3 gene dominated in adults and
the rib gene in neonates, but there were no
differences in protein expression between neo-
nates and adults. The differences in gene distri-
butions could be explained by differences in the
capsular serotype distribution of GBS strains
between adults and neonates (with serotype III
being most common in neonates and serotype V
in adults). There were no changes in the gene dis-
tribution or protein expression over time, which
contrasted with time-related changes in the cap-
sular serotype distribution of the same strains
(most importantly, an increase in serotype V) [5].
In conclusion, characterisation of invasive GBS
strains by investigating genes coding for surface
proteins can be used as a complement to capsular
serotyping of GBS. Based on the investigation of
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six genes encoding surface protein, 99% of the
invasive strains in the present study could be
characterised. Certain genes were significantly
more common in some capsular serotypes than in
others. The detection rate of the proteins studied
was rather low (51%), perhaps because of a high
proportion of serotype V isolates, but the results
of immunological typing were difficult to inter-
pret, and further investigations are needed to
identify reliable markers of protein expression.
Epidemiological studies of GBS are important for
the development of GBS vaccines suitable for use
in a range of geographical areas. Genes encoding
immunogenic surface proteins should therefore
be studied in different parts of the world and over
time. The present study identified many serovar-
iants for possible use in epidemiological studies
and the formulation of vaccines, but no single
surface protein included in this study appears to
be adequate for use in a successful GBS vaccine
on its own.
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